These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 27706215)

  • 1. Alterations of Myelin Content in Parkinson's Disease: A Cross-Sectional Neuroimaging Study.
    Dean DC; Sojkova J; Hurley S; Kecskemeti S; Okonkwo O; Bendlin BB; Theisen F; Johnson SC; Alexander AL; Gallagher CL
    PLoS One; 2016; 11(10):e0163774. PubMed ID: 27706215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa responsiveness in Parkinson's disease patients and white matter alterations in diffusion tensor imaging: a cross-sectional tract-based spatial statistics study.
    Zhou W; Jiang J; Peng W; Zhou X; Du J; Mo L; Tan C; Liu X; Chen L
    Neuroreport; 2021 May; 32(7):636-642. PubMed ID: 33850092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Susceptibility Mapping in Parkinson's Disease.
    Langkammer C; Pirpamer L; Seiler S; Deistung A; Schweser F; Franthal S; Homayoon N; Katschnig-Winter P; Koegl-Wallner M; Pendl T; Stoegerer EM; Wenzel K; Fazekas F; Ropele S; Reichenbach JR; Schmidt R; Schwingenschuh P
    PLoS One; 2016; 11(9):e0162460. PubMed ID: 27598250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson's Disease.
    Mueller K; Jech R; Ballarini T; Holiga Š; Růžička F; Piecha FA; Möller HE; Vymazal J; Růžička E; Schroeter ML
    Cerebellum; 2019 Apr; 18(2):212-224. PubMed ID: 30298443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
    Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS
    J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal changes of cortical microstructure in Parkinson's disease assessed with T1 relaxometry.
    Nürnberger L; Gracien RM; Hok P; Hof SM; Rüb U; Steinmetz H; Hilker R; Klein JC; Deichmann R; Baudrexel S
    Neuroimage Clin; 2017; 13():405-414. PubMed ID: 28116233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R2* relaxometry analysis for mapping of white matter alteration in Parkinson's disease with mild cognitive impairment.
    Kan H; Uchida Y; Ueki Y; Arai N; Tsubokura S; Kunitomo H; Kasai H; Aoyama K; Matsukawa N; Shibamoto Y
    Neuroimage Clin; 2022; 33():102938. PubMed ID: 34998126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
    Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
    Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.
    Kolind S; Seddigh A; Combes A; Russell-Schulz B; Tam R; Yogendrakumar V; Deoni S; Sibtain NA; Traboulsee A; Williams SC; Barker GJ; Brex PA
    Neuroimage Clin; 2015; 9():574-80. PubMed ID: 26594633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of integrity and atrophy in cingulate structural covariance networks in Parkinson's disease.
    de Schipper LJ; van der Grond J; Marinus J; Henselmans JML; van Hilten JJ
    Neuroimage Clin; 2017; 15():587-593. PubMed ID: 28652971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional gray matter changes and age predict individual treatment response in Parkinson's disease.
    Ballarini T; Mueller K; Albrecht F; Růžička F; Bezdicek O; Růžička E; Roth J; Vymazal J; Jech R; Schroeter ML
    Neuroimage Clin; 2019; 21():101636. PubMed ID: 30558868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes of brain structure in Parkinson's disease patients with mild cognitive impairment analyzed via VBM technology.
    Gao Y; Nie K; Huang B; Mei M; Guo M; Xie S; Huang Z; Wang L; Zhao J; Zhang Y; Wang L
    Neurosci Lett; 2017 Sep; 658():121-132. PubMed ID: 28823894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative susceptibility mapping of the midbrain in Parkinson's disease.
    Du G; Liu T; Lewis MM; Kong L; Wang Y; Connor J; Mailman RB; Huang X
    Mov Disord; 2016 Mar; 31(3):317-24. PubMed ID: 26362242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized double-blind multi-center trial of hydrogen water for Parkinson's disease: protocol and baseline characteristics.
    Yoritaka A; Abe T; Ohtsuka C; Maeda T; Hirayama M; Watanabe H; Saiki H; Oyama G; Fukae J; Shimo Y; Hatano T; Kawajiri S; Okuma Y; Machida Y; Miwa H; Suzuki C; Kazama A; Tomiyama M; Kihara T; Hirasawa M; Shimura H; Hattori N
    BMC Neurol; 2016 May; 16():66. PubMed ID: 27176725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multi-sequence MRI Study in Parkinson's Disease: Association Between Rigidity and Myelin.
    Cai J; Kim JL; Baumeister TR; Zhu M; Wang Y; Liu A; Lee S; McKeown MJ
    J Magn Reson Imaging; 2022 Feb; 55(2):451-462. PubMed ID: 34374158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
    Parkinson Study Group
    JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. White matter myelin profiles linked to clinical subtypes of Parkinson's disease.
    Baumeister TR; Kim JL; Zhu M; McKeown MJ
    J Magn Reson Imaging; 2019 Jul; 50(1):164-174. PubMed ID: 30444020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyneuropathy in levodopa-treated Parkinson's patients.
    Szadejko K; Dziewiatowski K; Szabat K; Robowski P; Schinwelski M; Sitek E; Sławek J
    J Neurol Sci; 2016 Dec; 371():36-41. PubMed ID: 27871444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.